|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||34.50 - 34.70|
|52 Week Range||26.30 - 34.70|
|Beta (3Y Monthly)||0.42|
|PE Ratio (TTM)||22.55|
|Forward Dividend & Yield||1.09 (3.18%)|
|1y Target Est||34.03|
The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, and grants Priority Review status to the applications.
Basel, 19 February 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company`s New Drug Applications (NDAs) and granted Priority ...
Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns Polatuzumab vedotin has shown significant potential to improve outcomes in ...
OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The FDA is expected to make a decision on approval by August 19, 2019. “Polatuzumab vedotin, a potential first-in-class antibody drug conjugate, in combination with bendamustine and Rituxan, improved clinical outcomes including survival in some people with relapsed or refractory diffuse large B-cell lymphoma compared to bendamustine and Rituxan alone,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development.
OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and pediatric patients with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumors who have either progressed following prior therapies or as initial therapy when there are no acceptable standard therapies, and for the treatment of people with metastatic, ROS1-positive non-small cell lung cancer (NSCLC). The FDA is expected to make a decision on approval by August 18, 2019. “Entrectinib represents a unique approach to cancer treatment that can potentially target a range of hard-to-treat and rare NTRK fusion-positive tumors regardless of their site of origin, as well as treat ROS1-positive non-small cell lung cancer,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development.
Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.
Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.
TOKYO—A new pill that can kill the flu virus in 24 hours with a single dose has become the most-prescribed influenza treatment in Japan, which is suffering through its worst flu season in two decades. The pill, called Xofluza, was discovered by Osaka-based Shionogi & Co. and it was approved last year by regulators in Japan and the U.S. In the U.S., it is marketed by Roche Holding AG’s Genentech unit. The drug quickly gained the top share in Japan, according to Shionogi’s data, in part because of its ease of use.
Trading data from OTC Markets Group shows that shares of government-sponsored entities Fannie Mae and Freddie Mac saw a dramatic increase in dollar trading volume last month. Common shares of Fannie Mae ...
This exciting area of cancer research could turn into a huge industry. How can investors potentially profit?
Macrogenics stock rocketed by triple digits Wednesday after the firm said its breast cancer treatment outperformed Roche's competing drug, the blockbuster Herceptin, in a late-stage study.
DoubleLine CEO Jeffrey Gundlach sat down with Yahoo Finance's Julia La Roche in an exclusive interview.
DoubleLine CEO Jeffrey Gundlach talks about the millennial generation, the nation's debt and possible candidates for the 2020 presidential election, with Yahoo Finance's Julia La Roche.
DoubleLine Capital CEO Jeffrey Gundlach shares his thoughts on market risks, the possibility of a recession, Fed policy and the 2020 election. He speaks exclusively with Yahoo Finance's Julia La Roche, Jen Rogers, Myles Udland and Andy Serwer.
Aurora Cannabis reported earnings for its second quarter. The company says it accounted for about 20% of all consumer sales across Canada for the quarter. Yahoo Finance's Jackie DeAngelis and Julia La Roche discuss.
Is it time to say goodbye to the travel selfie? Yahoo Finance's Zack Guzman & Julia La Roche, along with Frank CEO & Founder Charlie Javice, discuss with Flytographer CEO & Founder Nicole Smith.
Yahoo Finance's Zack Guzman and Julia La Roche discuss one countries basic income experiment with Charlie Javice, Frank founder and CEO.